Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Among late phase trials, Lixisenatide (n = 5) showed the lowest eligibility rates (5.8% Non-Asian US) due to strict HbA1c requirements (7.510%), while Dulaglutide (n = 7) showed the highest variability (SD = 46.2%)
Fe(III)-Shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis
This material is intended exclusively for laboratory research, analytical testing, and scientific study
Say Hello to a Happier, Healthier You
Diagnostics 13 , 2158 (2023)
Was it the gelatin
US$ 20.97
US$ 28.60
US$ 27.14
US$ 20.49
